MINIPRESS TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

PRAZOSIN (PRAZOSIN HYDROCHLORIDE)

제공처:

AA PHARMA INC

ATC 코드:

C02CA01

INN (국제 이름):

PRAZOSIN

복용량:

1MG

약제 형태:

TABLET

구성:

PRAZOSIN (PRAZOSIN HYDROCHLORIDE) 1MG

관리 경로:

ORAL

패키지 단위:

100/500

처방전 유형:

Prescription

치료 영역:

ALPHA-ADRENERGIC BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0111527001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2016-11-03

제품 특성 요약

PRESCRIBING INFORMATION
PRODUCT MONOGRAPH
PR
MINIPRESS
PRAZOSIN HYDROCHLORIDE TABLETS BP
TABLETS 1.0, 2.0 AND 5.0 MG
ANTIHYPERTENSIVE
AA Pharma Inc.
1165 Creditstone Road Unit #1
Vaughan, Ontario
L4K 4N7
Date of Revision:
February 19, 2021
Control No. 248447
2
PR
MINIPRESS
TABLETS 1.0, 2.0 AND 5.0 MG
Prazosin Hydrochloride Tablets BP
THERAPEUTIC CLASSIFICATION
Antihypertensive
ACTIONS AND CLINICAL PHARMACOLOGY
MINIPRESS is a formulation of prazosin hydrochloride and is a
conventional release formulation.
Prazosin causes a decrease in total peripheral resistance. Animal
studies suggest that the vasodilator
effect of prazosin is related to selective blockade of post-synaptic
alpha
1
- adrenoceptors. The results
of dog forelimb experiments demonstrate that the peripheral
vasodilator effect is confined mainly to
the level of the resistance vessels (arterioles). Hemodynamic studies
have been carried out in man
following acute single dose administration and during the course of
long term maintenance therapy.
The results confirm that the therapeutic effect is a fall in blood
pressure unaccompanied by a clinically
significant change in heart rate, renal blood flow and glomerular
filtration rate. In patients with
hypertension there is little change in cardiac output. In addition,
clinical pharmacology studies have
shown that both prazosin and prazosin GITS antagonize the vasopressor
effect of intravenous
phenylephrine, an alpha
1
-agonist.
In man blood pressure is lowered in both the supine and standing
positions. The hypotensive effect of
prazosin hydrochloride is greater when the patient is standing, and a
mild reflex tachycardia can
result. Tolerance has not been observed to develop in long term
hypertensive therapy. Rebound
elevation of blood pressure does not seem to occur following abrupt
cessation of therapy with
MINIPRESS.
Following oral administration of MINIPRESS in normal volunteers and
hypertensive patients, plasma
concentrations reach a peak at about 3 hours with a plasma half-life
of 2-3 hours. The drug is h